Kombination von MRT und PET erlaubt genauere Rezidivdiagnostik des Rektumkarzinoms durch Bildfusion

Zusammenfassung

Hintergrund: Es war das Ziel dieser Studie, die komplementäre diagnostische Wertigkeit der Magnetresonanztomografie (MRT) und der Positronenemissionstomografie (PET) bei Patienten mit Verdacht auf ein Rektumkarzinomrezidiv zu evaluieren. Dabei umfasste die integrierte MRT-Untersuchung sowohl hochaufgelöste, stationäre Sequenzen des Beckens wie auch eine Abklärung von Thorax und Abdomen bei kontinuierlicher Tischbewegung in gleicher Sitzung. Die Möglichkeit einer verbesserten Diagnostik mithilfe der Bildfusion von MRT und PET wurde überprüft. Patienten und Methodik: In diese retrospektive Studie wurden 31 Patienten eingeschlossen, die aufgrund eines klinischen Verdachts auf ein Rektumkarzinomrezidiv eine integrierte MRT-Untersuchung und eine ¹⁸F-FDG-PET in einem Zeitraum von maximal 30 Tagen erhalten hatten. MRT, PET und die Kombination beider Verfahren inklusive von Fusionsbildern wurden separat von 2 erfahrenen Befundern ausgewertet. Für jede detektierbare Läsion wurde die Wahrscheinlichkeit für einen malignen Befund auf einer Likert-Skala von 1 bis 5 im Konsensus eingeschätzt. Histologie und Verlaufskontrollen bildeten den Referenzstandard. Die diagnostischen Genauigkeiten wurden mit einer abgewandelten Receiver-Operator-Charakteristik (jackknife free response receiver operator characteristic; JAFROC) bestimmt. Die Sensitivitäten wurden für „sicher maligne“ und „wahrscheinlich maligne“ Läsionen berechnet. Ergebnisse: Der Referenzstandard umfasste 150 maligne Läsionen (48 Lokalbefunde, 102 Metastasen). Die JAFROC-Analyse zeigte diagnostische Genauigkeiten von 0,73 für die MRT alleine, von 0,63 für die PET alleine und 0,83 für die Kombination beider Modalitäten. Die entsprechenden Sensitivitäten betrugen 85,4, 52,1 und 95,8 % für Lokalbefunde und 61,8, 47,1 und 81,4 % für Metastasen. Schlussfolgerung: Die Kombination von lokaler MRT, der thorakoabdominellen MRT bei kontinuierlicher Tischbewegung und der FDG-PET kann mithilfe der Bildfusion die Erkennbarkeit von Läsionen bei Patienten mit einem Rektumkarzinomrezidiv verbessern.

Abstract

Purpose: It was the aim of this study to investigate the complementary diagnostic performance of a combined pelvic and thoracoabdominal magnetic resonance imaging (MRI) examination and positron emission tomography (PET) enhanced by image fusion in patients with suspected rectal cancer recurrence. Patients and Methods: Thirty-one patients with clinically suspected recurrence from rectal cancer were retrospectively included, who had received MRI (high resolution pelvic MRI combined with thoracoabdominal MRI performed during continuous table translation) and ¹⁸F-FDG-PET within 30 days. MRI alone, PET alone, and MRI and PET combined including fusion images were analysed by two observers in consensus. The likelihood of malignancy of all detectable lesions was rated on a 5-point Likert scale. The standard of reference consisted of histopathology and follow-up imaging. Confidence ratings were analysed with a jackknife free response receiver-operator characteristic paradigm (JAFROC). Further test characteristics were derived by considering “probably malignant” and “definitely malignant” lesions as positive test results. Results: The reference standard comprised 150 malignant lesions (48 local, 102 distant). JAFROC analysis revealed overall figures-of-merit of 0.73 for MRI, 0.63 for PET, and 0.83 for the combined approach (differences significant). The sensitivities of MRI, PET and the combined approach were 85.4, 52.1, and 95.8 % for local recurrence and 61.8, 47.1, and 81.4 % for distant recurrence, respectively. Conclusion: The combination of local high-resolution MRI, thoracoabdominal continuously moving table MRI and FDG-PET supported by image fusion improves lesion detection in recurrent rectal cancer.

Schlüsselwörter

Rektumkarzinom - Rezidiv - Metastasen - Magnetresonanztomografie - Positronenemissionstomografie

Key words

rectal cancer - recurrence - metastases - magnetic resonance imaging - positron emission tomography

• Literatur

• 1 Gaedcke J, Liersch T, Hess C et al. [Rectal cancer: current status of multimodal therapy–when and how?]. Zentralbl Chir 2011; 136: 334-342
• 2 Bhangu A, Ali SM, Darzi A et al. Meta-analysis of survival based on resection margin status following surgery for recurrent rectal cancer. Colorectal Dis 2012; 14: 1457-1466
• 3 Schaefer O, Langer M. Detection of recurrent rectal cancer with CT, MRI and PET/CT. Eur Radiol 2007; 17: 2044-2054
• 4 Harji DP, Sagar PM. Advancing the surgical treatment of locally recurrent rectal cancer. Br J Surg 2012; 99: 1169-1171
• 5 Dresen RC, Kusters M, Daniels-Gooszen AW et al. Absence of tumor invasion into pelvic structures in locally recurrent rectal cancer: prediction with preoperative MR imaging. Radiology 2010; 256: 143-150
• 6 Even-Sapir E, Parag Y, Lerman H et al. Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology 2004; 232: 815-822
• 7 Faneyte IF, Dresen RC, Edelbroek MA et al. Pre-operative staging with positron emission tomography in patients with pelvic recurrence of rectal cancer. Dig Surg 2008; 25: 202-207
• 8 Fiocchi F, Iotti V, Ligabue G et al. Contrast-enhanced MRI and PET-CT in the evaluation of patients with suspected local recurrence of rectal carcinoma. Radiol Med 2010; 115: 906-919
• 9 Huebner RH, Park KC, Shepherd JE et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000; 41: 1177-1189
• 10 Kau T, Reinprecht P, Eicher W et al. FDG PET/CT in the detection of recurrent rectal cancer. Int Surg 2009; 94: 315-324
• 11 Lambregts DM, Cappendijk VC, Maas M et al. Value of MRI and diffusion-weighted MRI for the diagnosis of locally recurrent rectal cancer. Eur Radiol 2011; 21: 1250-1258
• 12 Shamim SA, Kumar R, Halanaik D et al. Role of FDG-PET/CT in detection of recurrent disease in colorectal cancer. Nucl Med Commun 2010; 31: 590-596
• 13 Bamba Y, Itabashi M, Kameoka S. Management of local recurrence of colorectal cancer: the role of PET/CT. Abdom Imaging 2011; 36: 322-326
• 14 Fautz HP, Kannengiesser SA. Sliding multislice (SMS): a new technique for minimum FOV usage in axial continuously moving-table acquisitions. Magn Reson Med 2006; 55: 363-370
• 15 Chakraborty DP. Recent advances in observer performance methodology: jackknife free-response ROC (JAFROC). Radiat Prot Dosimetry 2005; 114: 26-31
• 16 Combs SE, Kieser M, Habermehl D et al. Phase I/II trial evaluating carbon ion radiotherapy for the treatment of recurrent rectal cancer: the PANDORA-01 trial. BMC Cancer 2012; 12: 137
• 17 Guo S, Reddy CA, Kolar M et al. Intraoperative radiation therapy with the photon radiosurgery system in locally advanced and recurrent rectal cancer: retrospective review of the Cleveland clinic experience. Radiat Oncol 2012; 7: 110
• 18 Harji DP, Griffiths B, McArthur DR et al. Surgery for recurrent rectal cancer: higher and wider?. Colorectal Dis 2013; 15: 139-145
• 19 Koom WS, Choi Y, Shim SJ et al. Reirradiation to the pelvis for recurrent rectal cancer. J Surg Oncol 2012; 105: 637-642
• 20 Milani V, Pazos M, Issels RD et al. Radiochemotherapy in combination with regional hyperthermia in preirradiated patients with recurrent rectal cancer. Strahlenther Onkol 2008; 184: 163-168
• 21 Rhomberg W, Hammer J, Sedlmayer F et al. Irradiation with and without razoxane in the treatment of incompletely resected or inoperable recurrent rectal cancer. Results of a small randomized multicenter study. Strahlenther Onkol 2007; 183: 380-384
• 22 Wang Z, Lu J, Liu L et al. Clinical application of CT-guided (125)I seed interstitial implantation for local recurrent rectal carcinoma. Radiat Oncol 2011; 6: 138
• 23 Lambregts DM, Maas M, Cappendijk VC et al. Whole-body diffusion-weighted magnetic resonance imaging: current evidence in oncology and potential role in colorectal cancer staging. Eur J Cancer 2011; 47: 2107-2116
• 24 Huppertz A, Franiel T, Wagner M et al. Whole-body MRI with assessment of hepatic and extraabdominal enhancement after administration of gadoxetic acid for staging of rectal carcinoma. Acta Radiol 2010; 51: 842-850
• 25 Huppertz A, Schmidt M, Wagner M et al. Whole-body MR imaging versus sequential multimodal diagnostic algorithm for staging patients with rectal cancer: cost analysis. Rofo 2010; 182: 793-802
• 26 Schmidt GP, Baur-Melnyk A, Haug A et al. Whole-body MRI at 1.5 T and 3 T compared with FDG-PET-CT for the detection of tumour recurrence in patients with colorectal cancer. Eur Radiol 2009; 19: 1366-1378
• 27 Baumann T, Ludwig U, Pache G et al. Continuously moving table MRI with sliding multislice for rectal cancer staging: image quality and lesion detection. Eur J Radiol 2010; 73: 579-587
• 28 Baumann T, Ludwig U, Pache G et al. Detection of pulmonary nodules with move-during-scan magnetic resonance imaging using a free-breathing turbo inversion recovery magnitude sequence. Invest Radiol 2008; 43: 359-367
• 29 Schaefer AO, Langer M, Baumann T. Continuously moving table MRI in oncology. Rofo 2010; 182: 954-964
• 30 Schwenzer NF, Schraml C, Muller M et al. Pulmonary lesion assessment: comparison of whole-body hybrid MR/PET and PET/CT imaging–pilot study. Radiology 2012; 264: 551-558